{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:37:51Z","timestamp":1793144271449,"version":"4.5.0"},"reference-count":47,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"unspecified","delay-in-days":26,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Bristol Myers Squibb","award":["NCT03215927"],"award-info":[{"award-number":["NCT03215927"]}]},{"DOI":"10.13039\/100000069","name":"NIAMS","doi-asserted-by":"crossref","award":["K23 AR081423-01"],"award-info":[{"award-number":["K23 AR081423-01"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2024,10,21]]},"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To explore the association between the extent of CT abnormalities by quantitative imaging analysis (QIA) and clinical\/physiological disease parameters in patients with antisynthetase syndrome associated interstitial lung disease (ARS-ILD).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We analysed 20 patients with antisynthetase antibodies and active ILD enrolled in the Abatacept in Myositis-Associated Interstitial Lung Disease study. High-resolution chest CT was obtained at weeks 0, 24 and 48 and QIA scored the extent of ground glass (quantitative score for ground glass), fibrosis (quantitative score for lung fibrosis, QLF) and total ILD (quantitative ILD, QILD). Mixed-effects models estimated longitudinal QIA scores over time. Associations between QIA scores with clinical\/physiological parameters were analysed longitudinally using repeated-measures mixed-effects models.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Patients were median age 57 years, 55% males and 85% white. Higher (worse) baseline QIA scores correlated with lower baseline forced vital capacity (FVC) and diffusing capacity adjusted for haemoglobin (DLCO). Longitudinal QIA trajectories trended towards improving scores during the trial, and patients on O<jats:sub>2<\/jats:sub> at baseline had worsening QIA trajectories which were different from patients who were not on O<jats:sub>2<\/jats:sub>. Longitudinal QIA scores demonstrated strong associations with both FVC and DLCO over time. Higher QILD scores over time were also associated with worse dyspnoea scores, pulmonary visual analogue scale, physician and patient global disease activity, health status in 6\/8 domains of the Short Form-36 and higher oxygen requirements. Patients with significant radiographic improvement at 48 weeks had higher baseline QLF, QILD and worse DLCO.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Longitudinal QIA scores associate with lung physiology, patient perception of respiratory status, overall disease activity and quality of life over time in ARS-ILD. QIA may allow reproducible monitoring of disease progression and response to therapy over time.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03215927\">NCT03215927<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2024-004592","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T04:16:07Z","timestamp":1732767367000},"page":"e004592","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Relationship between high-resolution computed tomography quantitative imaging analysis and physiological and clinical features in antisynthetase syndrome-related interstitial lung disease"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct03215927","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03215927","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03215927","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7216-7219","authenticated-orcid":false,"given":"Sangmee Sharon","family":"Bae","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, University of California Los Angeles, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fereidoun","family":"Abtin","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of California Los Angeles, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of California Los Angeles, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Markovic","sequence":"additional","affiliation":[{"name":"Department of Medicine Statistics Core, University of California Los Angeles, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cato","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of California Los Angeles, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siamak","family":"Moghadam-Kia","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chester V","family":"Oddis","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Pulmonology and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galina","family":"Marder","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Northwell Health, New Hyde Park, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swamy","family":"Venuturupalli","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul F","family":"Dellaripa","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy J","family":"Doyle","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary Matt","family":"Hunninghake","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Falk","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Pulmonary and Critical Care Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1768-7019","authenticated-orcid":false,"given":"Christina","family":"Charles-Schoeman","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, University of California Los Angeles, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald P","family":"Tashkin","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of California Los Angeles, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Goldin","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of California Los Angeles, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7531-8038","authenticated-orcid":false,"given":"Rohit","family":"Aggarwal","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"key":"2025090313221455000_10.4.e004592.1","doi-asserted-by":"publisher","DOI":"10.1097\/CPM.0000000000000171"},{"key":"2025090313221455000_10.4.e004592.2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-011-1840-0"},{"key":"2025090313221455000_10.4.e004592.3","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1007\/s00296-017-3799-x","article-title":"Mortality and prognostic factors in idiopathic inflammatory myositis: a retrospective analysis of a large multicenter cohort of Spain","volume":"37","author":"Nu\u00f1o-Nu\u00f1o","year":"2017","journal-title":"Rheumatol Int"},{"key":"2025090313221455000_10.4.e004592.4","doi-asserted-by":"crossref","first-page":"v59","DOI":"10.1093\/rheumatology\/ken271","article-title":"High-resolution computed tomography and scleroderma lung disease","volume":"47 Suppl 5","author":"Wells","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"2025090313221455000_10.4.e004592.5","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201711-2174OC"},{"key":"2025090313221455000_10.4.e004592.6","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00869-2018","article-title":"Predicting outcomes in rheumatoid arthritis related interstitial lung disease","volume":"53","author":"Jacob","year":"2019","journal-title":"Eur Respir J"},{"key":"2025090313221455000_10.4.e004592.7","doi-asserted-by":"publisher","DOI":"10.1378\/chest.07-2444"},{"key":"2025090313221455000_10.4.e004592.8","doi-asserted-by":"publisher","DOI":"10.1136\/thx.47.9.738"},{"key":"2025090313221455000_10.4.e004592.9","doi-asserted-by":"publisher","DOI":"10.1002\/art.30438"},{"key":"2025090313221455000_10.4.e004592.10","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/art.41085","article-title":"Using Transitional Changes on High-Resolution Computed Tomography to Monitor the Impact of Cyclophosphamide or Mycophenolate Mofetil on Systemic Sclerosis-Related Interstitial Lung Disease","volume":"72","author":"Kim","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2025090313221455000_10.4.e004592.11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2174\/1874306402014010022","article-title":"Effects of Nintedanib on Quantitative Lung Fibrosis Score in Idiopathic Pulmonary Fibrosis","volume":"14","author":"Lancaster","year":"2020","journal-title":"Open Respir Med J"},{"key":"2025090313221455000_10.4.e004592.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2018.08.1058"},{"key":"2025090313221455000_10.4.e004592.13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S2213-2600(19)30262-0","article-title":"Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"8","author":"Richeldi","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2025090313221455000_10.4.e004592.14","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(16)30152-7"},{"key":"2025090313221455000_10.4.e004592.15","doi-asserted-by":"crossref","first-page":"3690","DOI":"10.1093\/rheumatology\/kead122","article-title":"Quantitative interstitial lung disease scores in idiopathic inflammatory myopathies: longitudinal changes and clinical implications","volume":"62","author":"Yeo","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2025090313221455000_10.4.e004592.16","first-page":"S26","article-title":"A computer-aided diagnosis system for quantitative scoring of extent of lung fibrosis in scleroderma patients","volume":"28","author":"Kim","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"2025090313221455000_10.4.e004592.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.acra.2008.03.011"},{"key":"2025090313221455000_10.4.e004592.18","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12010120","article-title":"Quantitative Computed Tomography Lung COVID Scores with Laboratory Markers: Utilization to Predict Rapid Progression and Monitor Longitudinal Changes in Patients with Coronavirus 2019 (COVID-19) Pneumonia","volume":"12","author":"Kang","year":"2024","journal-title":"Biomedicines"},{"key":"2025090313221455000_10.4.e004592.19","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1164\/rccm.201709-1845OC","article-title":"Reliability and minimal clinically important differences of forced vital capacity: Results from the Scleroderma Lung Studies (SLS-I and SLS-II)","volume":"197","author":"Kafaja","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2025090313221455000_10.4.e004592.20","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.chest.2021.11.033","article-title":"Early Radiographic Progression of Scleroderma: Lung Disease Predicts Long-term Mortality","volume":"161","author":"Volkmann","year":"2022","journal-title":"Chest"},{"key":"2025090313221455000_10.4.e004592.21","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.232558","article-title":"Fleischner Society: Glossary of Terms for Thoracic Imaging","volume":"310","author":"Bankier","year":"2024","journal-title":"Radiology"},{"key":"2025090313221455000_10.4.e004592.22","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202202-0399ST"},{"key":"2025090313221455000_10.4.e004592.23","doi-asserted-by":"publisher","DOI":"10.1378\/chest.113.3.619"},{"key":"2025090313221455000_10.4.e004592.24","first-page":"S118","article-title":"Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient\/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)\/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI)","volume":"63 Suppl 11","author":"Rider","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090313221455000_10.4.e004592.25","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00150414"},{"key":"2025090313221455000_10.4.e004592.26","doi-asserted-by":"publisher","DOI":"10.1249\/00005768-198205000-00012"},{"key":"2025090313221455000_10.4.e004592.27","doi-asserted-by":"crossref","DOI":"10.1177\/2050312116671725","article-title":"SF-36 total score as a single measure of health-related quality of life: Scoping review","volume":"4","author":"Lins","year":"2016","journal-title":"SAGE Open Med"},{"key":"2025090313221455000_10.4.e004592.28","unstructured":"U.S. Food and Drug Administration (FDA) . The voice of the patient: a series of reports from the U.S. Food and Drug Administration\u2019s (FDA\u2019s) patient-focused drug development initiative. Idiopathic pulmonary fibrosis. 2015."},{"key":"2025090313221455000_10.4.e004592.29","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00034805"},{"key":"2025090313221455000_10.4.e004592.30","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201908-1590ST"},{"key":"2025090313221455000_10.4.e004592.31","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00016-2016","article-title":"2017 ERS\/ATS standards for single-breath carbon monoxide uptake in the lung","volume":"49","author":"Graham","year":"2017","journal-title":"Eur Respir J"},{"key":"2025090313221455000_10.4.e004592.32","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.E0016-2016"},{"key":"2025090313221455000_10.4.e004592.33","doi-asserted-by":"crossref","unstructured":"Stanojevic S , Graham BL , Cooper BG , et al . Global Lung Function Initiative Twg, Global Lung Function Initiative T. Official ERS technical standards: Global Lung Function Initiative reference values for the carbon monoxide transfer factor for Caucasians. Eur Respir J 2017;50. doi:10.1183\/13993003.00010-2017","DOI":"10.1183\/13993003.00010-2017"},{"key":"2025090313221455000_10.4.e004592.34","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00080312"},{"key":"2025090313221455000_10.4.e004592.35","unstructured":"Menard S . Standardized Regression Coefficients. Thousand Oaks, CA, USA: Sage Publications, 2004."},{"key":"2025090313221455000_10.4.e004592.36","unstructured":"Wooldridge JM . Econometric analysis of cross section and panel data. The MIT Press; 2010."},{"key":"2025090313221455000_10.4.e004592.37","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206076"},{"key":"2025090313221455000_10.4.e004592.38","doi-asserted-by":"publisher","DOI":"10.1097\/01.rti.0000213572.16904.40"},{"key":"2025090313221455000_10.4.e004592.39","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.173.4.10511155"},{"key":"2025090313221455000_10.4.e004592.40","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-021-01790-0","article-title":"Validation and minimum important difference of the UCSD Shortness of Breath Questionnaire in fibrotic interstitial lung disease","volume":"22","author":"Chen","year":"2021","journal-title":"Respir Res"},{"key":"2025090313221455000_10.4.e004592.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2012.06.018"},{"key":"2025090313221455000_10.4.e004592.42","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0087-2022","article-title":"The 6-min walk test as a primary end-point in interstitial lung disease","volume":"31","author":"Harari","year":"2022","journal-title":"Eur Respir Rev"},{"key":"2025090313221455000_10.4.e004592.43","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1093\/rheumatology\/keac184","article-title":"Automated quantification system predicts survival in rheumatoid arthritis-associated interstitial lung disease","volume":"61","author":"Oh","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2025090313221455000_10.4.e004592.44","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu289"},{"key":"2025090313221455000_10.4.e004592.45","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.ejrad.2016.05.012","article-title":"Antisynthetase syndrome: Pulmonary computed tomography findings of adult patients with antibodies to aminoacyl-tRNA synthetases","volume":"85","author":"Waseda","year":"2016","journal-title":"Eur J Radiol"},{"key":"2025090313221455000_10.4.e004592.46","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1097\/TP.0000000000003950","article-title":"Quantitative Image Analysis at Chronic Lung Allograft Dysfunction Onset Predicts Mortality","volume":"106","author":"Weigt","year":"2022","journal-title":"Transplantation"},{"key":"2025090313221455000_10.4.e004592.47","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10173812","article-title":"The Extent and Diverse Trajectories of Longitudinal Changes in Rheumatoid Arthritis Interstitial Lung Diseases Using Quantitative HRCT Scores","volume":"10","author":"Lee","year":"2021","journal-title":"J Clin Med"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2024-004592","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:22:28Z","timestamp":1756930948000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2024-004592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":47,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,11,27]]},"published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1136\/rmdopen-2024-004592"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2024-004592","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]}}}